Anthracycline cardiomyopathy
Pronunciation: an-thruh-SY-kleen kar-dee-oh-my-OP-uh-thee
Chemotherapy-induced heart muscle disease caused by anthracycline antibiotics, characterized by progressive left ventricular dysfunction.
Full Definition
Anthracycline cardiomyopathy is a well-recognized form of chemotherapy-induced cardiac toxicity resulting from treatment with anthracycline antibiotics such as doxorubicin, daunorubicin, and epirubicin. This condition is characterized by dose-dependent myocardial injury leading to progressive left ventricular systolic dysfunction and potentially irreversible heart failure. The pathophysiology involves oxidative stress, mitochondrial dysfunction, and cardiomyocyte apoptosis. Risk factors include cumulative dose, patient age, concurrent radiation therapy, and pre-existing cardiovascular disease. Early detection through serial cardiac monitoring is crucial for timely intervention and optimization of cancer treatment protocols.
Usage
Usage note: Specify the causative agent when known (e.g., doxorubicin-induced cardiomyopathy) for greater precision in clinical documentation.
In Context
- "Serial echocardiograms were performed to monitor for anthracycline cardiomyopathy during the treatment course." — Oncology treatment plan
- "The patient developed anthracycline cardiomyopathy with LVEF decline from 60% to 35% after completing chemotherapy." — Cardio-oncology consultation note